- FDA Review of Clinical Data Agalsidase alfa for treatment of Fabry Disease
- FDA Review of Clinical Data Fragmin ® (Dalteparin sodium injection) for treatment of VTE in cancer patients
- FDA Review of Clinical Data Laronidase for the treatment of Mucopolysaccharidosis I
- FDA Review of Clinical Safety Data Omalizumab for treatment of Allergic Asthma Genentech, Inc.
- FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS
- FDA Review Perspective – Entecavir for Hepatitis B
- FDA Review Session December 7, 2010
- FDA Review Team for Genasense (G3139)
- FDA Risk/Benefit Considerations
- FDA Risk Communication
- FDA Role in Post-licensure Vaccine Safety Evaluation
- FDA’s 510(k) Process: Reform or Ruin?
- FDA’s 510(k) Third-Party Review Program
- FDA’s 513(g) What is it?
- FDA’s Access Mechanisms When They Work – When They Don’t And Why
- FDA's Add-On Inspections for 21 CFR 11
- FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Overview
- FDA’s Antiviral Drugs Advisory Committee Meeting
- FDA’s BIMO Inspection Program and IRB Inspections
- FDA’s Budget Challenge August 22, 2007 Wayne Pines
- FDA’s Center for Biologics Evaluation and Research Initiatives and Current Priorities Robert A. Yetter, Ph.D. Associate
- FDA’s Center for Tobacco Products
- September X , 2018
- FDA s Clinical Investigator Course
- FDA s Clinical Investigator Course
- FDA s Clinical Investigator Course
- FDA s Clinical Investigator Course
- FDA s Clinical Investigator Course
- FDA s Clinical Investigator Course
- FDA’s Clinical Investigator Course
- FDA’s Criteria for Evaluation of Red Blood Cell Products
- FDA’s “Critical Path” Initiative
- FDA’s “Critical Path” Initiative Presentation to FDA Science Board
- FDA’s Critical Path Research Initiative & Intro to the CBER Research Program
- FDA’s Critical Path to Medical Product Development: Opportunities for Generic Drugs
- FDA s Current Considerations of Parvovirus B19 Nucleic Acid Testing NAT
- FDA’s Current Thinking on B19 NAT (Policy Pending)
- FDA’s Current Thinking on B19 NAT (Policy Pending)
- FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Meeting
- FDA’s Evolving SaMD Regulation: Key Updates for Ophthalmologists
- FDA’s Final Policy on Single-Use Devices Reprocessed by Hospitals and Commercial Reprocessors
- FDA’S FOOD BIOTECHNOLOGY POLICY
- FDA’s Food Related Emergency Exercise – Boxed Set (FREE-B)
- FDA’s Framework for Reviewing Regulations
- FDA’s Framework for Reviewing Regulations
- FDA’s History with Lab Developed Tests
- FDA’s Medical Device Program 2013: Looking Back and Looking Ahead
- FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public
- FDA’s new draft guidance on best practices for selecting predicate devices for 510(k) notifications!
- FDA's New Enforcement of 21 CFR Part 11
- FDA's on-going Part 11 Inspection Program
- FDA’s Oncologic Drugs Advisory Committee Meeting
- FDA’s Osteoporosis Guidance
- FDA’s Oversight of Clinical Trials Overview of GCP Bioresearch Monitoring Program
- FDA’s Pesticide Program
- FDA’s Pharmaceutical Inspectorate
- FDA’s Policies, Procedures, and Systems: Effects on Provider and Information Technology Sectors
- FDA s Proposed Revised 21 CFR 207 Rule and Electronic Drug Registration and Listing Systems e-DRLS
- FDA’s Proposed Rule under FSMA for Preventive Controls Key Takeaways May 17, 2013
- FDA’s Rapid Response Teams (RRT) Program Update
- FDA’s Refreshed Packaged Food Label
- FDA’s Regulatory Development Timeline
- FDA’s Revamped Medical Device Security Requirements- Gatekeeper that can Hold Medical Device’s Approval!
- FDA’s Role in Encouraging Innovation in Combination Products
- FDA’s Role in Plant Design Reviews
- FDA’s Role in Plant Design Reviews
- FDA’s Role in Plant Design Reviews
- FDA’s Role in Protecting Your Child’s Health Through Safe and Effective Vaccines
- FDA’s Sentinel Initiative and CBER's Analytic Epidemiology Branch
- FDA’s Sentinel Initiative
- FDA’s Third Annual MDUFMA Stakeholder Meeting November 17, 2005
- FDA’s vCJD Risk Communication on US Plasma-Derived Factor VIII and UK Plasma-Derived Factor XI
- FDA Safety and Innovation Act FDASIA
- FDA Safety Event Reporting
- FDA Science Board
- FDA Science Board, April 2003
- FDA Science Board
- FDA Science Board
- FDA scripts. Programming and validation of script/programs.
- FDA scripts. V alidation of script/programs.
- FDA Software Validation - ADB
- FDA Stakeholder Meeting On Implementation of MDUFMA Review Performance Goals May 22, 2006
- FDA Stakeholders Meeting on Disparities Oakland, CA February 2011
- FDA Standards Development and Implementation
- FDA statisticians reviewed submissions with accelerated stability testing
- FDA statisticians reviewed submissions with accelerated stability testing
- FDA Summary
- FDA Summary
- FDA Summary
- FDA Sunlamp Guidance Policies: Successfully Implemented
- FDA Survey of Lead in Pharmaceuticals
- FDA TA Initiative Project Plan
- Evolving Safety Issues Associated With Erythropoietin Products Oncology Drugs Advisory Committee May 4, 2004
- FDA Team
- FDA Thailand
- FDA, THE PRIVATE LABORATORY AND ITS IMPACT ON TRADE
- FDA Tissue Residue Reduction Efforts
- FDA to CONNECT
- FDA To Facilitate Timely Development Of Safe, Effective COVID-19 Vaccines
- FDA to release guidance for assessing PRO’s in all clinical trials (4th quarter 2005?)
- FDA Tobacco Product Regulation: Regulatory History and Overview of Pending Legislation
- FDA Tox Working Group
- Council of Independent Tobacco Manufacturers of America (CITMA) David M Johnson, PhD., CITMA Consultant
- FDA Transmissible Spongiform Encephalopathies Advisory Committee 23rd Meeting 01 August 2011 Gaithersburg MD Donor Defe
- FDA Tree Nut Risk Assessment and Human Salmonellosis
- FDA TSE Advisory Committee 16 th Meeting Silver Spring MD 14 October 2004 David M. Asher, MD
- FDA TSE Advisory Committee Meeting February 13, 2004; Topic 4D Minimizing the Risk of TSE in CDER - Regulated Products
- FDA TSE Advisory Committee Meeting July 17, 2003 U.S. Market Dynamics for Bovine Bone Gelatin George E. Masson Preside
- FDA UDI
- FDA UDI
- FDA Update
- FDA Update
- FDA Update 2011 presented by Bennett Napier, CAE
- FDA Update - CDRH
- FDA Update New Expectations for IRBs